These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9308766)

  • 1. A type 2b von Willebrand disease mutation (Ile546-->Val) associated with an unusual phenotype.
    Federici AB; Mannucci PM; Stabile F; Canciani MT; Di Rocco N; Miyata S; Ware J; Ruggeri ZM
    Thromb Haemost; 1997 Sep; 78(3):1132-7. PubMed ID: 9308766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers.
    Weiss HJ; Sussman II
    Blood; 1986 Jul; 68(1):149-56. PubMed ID: 3487353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children.
    Frontroth JP; Hepner M; Sciuccati G; Feliú Torres A; Pieroni G; Bonduel M
    Thromb Haemost; 2010 Dec; 104(6):1158-65. PubMed ID: 20941465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation.
    Shen MC; Lin JS; Lin DS; Hsu SC; Lin B
    Thromb Res; 2003; 112(5-6):291-5. PubMed ID: 15041272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor.
    Gaucher C; de Romeuf C; Rauïs-Morret M; Corazza F; Fondu P; Mazurier C
    Thromb Haemost; 1995 Apr; 73(4):610-6. PubMed ID: 7495067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Randi AM; Shindler KS; Tuley EA; Rustagi PK; Sadler JE
    J Biol Chem; 1993 Sep; 268(27):20497-501. PubMed ID: 8376405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
    J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
    Miller JL; Kupinski JM; Castella A; Ruggeri ZM
    J Clin Invest; 1983 Nov; 72(5):1532-42. PubMed ID: 6415113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.
    Ribba AN; Hilbert L; Lavergne JM; Fressinaud E; Boyer-Neumann C; Ternisien C; Juhan-Vague I; Goudemand J; Girma J; Mazurier C; Meyer D
    Blood; 2001 Feb; 97(4):952-9. PubMed ID: 11159522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand's disease with spontaneous platelet aggregation induced by an abnormal plasma von Willebrand factor.
    Grainick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    J Clin Invest; 1985 Oct; 76(4):1522-9. PubMed ID: 2932469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.
    Casonato A; Cattini MG; Soldera C; Marcato S; Sartorello F; Pontara E; Pagnan A
    J Lab Clin Med; 2004 Nov; 144(5):254-9. PubMed ID: 15570243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.